Cilnidipine as an agent to lower blood pressure without sympathetic nervous activation as demonstrated by iodine-123 metaiodobenzylguanidine imaging in rat hearts

Annals of Nuclear Medicine

Volumn 17, Issue 4, 2003, Pages 321-326

  Sakaki, Takatoshi ^a   Naruse, Hitoshi ^a   Masai, Miho ^a   Takahashi, Keiko ^a   Ohyanagi, Mitsumasa ^a   Iwasaki, Tadaaki ^a   Fukuchi, Minoru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

MIBG; Myocardial sympathetic nervous activation; N type Ca channel blocker; Washout rate

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE; DIHYDROPYRIDINE DERIVATIVE; NIFEDIPINE; NORADRENALIN; WATER;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY MUSCLE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CHANNEL GATING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL MODEL; HEART RATE; HYPERTENSION; IMAGE ANALYSIS; IMAGING SYSTEM; ISCHEMIC HEART DISEASE; NERVE ENDING; NONHUMAN; NORADRENALIN BLOOD LEVEL; OUTCOMES RESEARCH; PARAMETER; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RAT; RAT STRAIN; STOMACH TUBE; SYMPATHETIC NERVE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

EID: 0043015747     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988529     Document Type: Article

References (20)

1. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
2. Furberg CD, Psaty BM. Corrections to the nifedipine metaanalysis. Circulation 1996; 93: 1475-1476.
3. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187-1192.
4. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. for Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
5. Grossman E, Messerlit FH. Effect of calcium antagonists on sympathetic activity. Eur Heart 1998; 19 (suppl F): F27-31.
6. ++ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997; 280: 1184-1191.
7. 2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br J Pharmacol 1997; 122: 37-42.
8. Mortara A, La Rovere MT, Signorini MG, Pantaleo P, Pinna G, Martinelli L, et al. Can power spectral analysis of heart rate variability identify a high risk subgroup of congestive heart failure patients with excessive sympathetic activation? A pilot study before and after transplantation. Br Heart J 1994; 71: 422-430.
9. Merlet P, Valette H, Dubois-Rande J, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477.
10. Morozumi T, Ishida Y, Kusuoka H, Sato H, Hori M, Kamada T, et al. Effect of β-blockade on regional left ventricular function in patients with dilated cardiomyopathy. J Nucl Cardio 1995; 2: 231-237.
11. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 metaiodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12: 1252-1258.
12. Sakata K, Shirotani M, Yoshida H, Kurata C. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 1998; 32: 438-443.
13. Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, et al. The effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 1999; 33 (6): 1447-1452.
14. Kohno M, et al. Effect of FRC-8653 (cilnidipine) on hemodynamics, the renin-angiotensin system, the sympathetic nervous system, and atrial natriuretic polypeptides at exercise loading in patients with essential hypertension. Jpn Pharmacol Ther 1993; 21 (Suppl 1): S227-232. (in Japanese)
15. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986; 59: 178-193.
16. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu J, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22: 22-31.
17. Watanabe K, Dozen M, Maeda E, Hosono M, Kase N, Ikeda K, et al. General pharmacological studies of 2-Methoxyethyl(E)-3-phenyl-2-propen-1-yl(±)-1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (FRC-8653), a new antihypertensive drug. Pharmacometrics 1992; 44 (4): 443-463. (in Japanese)
18. Hosono M, Dozen M, Hiruma T, Hujii S, Watanabe K, Hayashi Y. Changes in heart rate and plasma norepinephrine level of conscious spontaneously hypertensive rats treated with cilnidipine (FRC-8653). Jpn Pharmacol Ther 1995; 23: 3029-3040. (in Japanese)
19. Chiueh CC, Kopin IJ. Hyperresponsivity of spontaneously hypertensive rat to indirect measurement of blood pressure. Am J Physiol 1978; 234 (6): H690-695.
20. Yamaguti I, Kopin IJ. Blood pressure, plasma catecholamines, and sympathetic outflow in pithed SHR and WKY rats. Am J Physiol 1980; 238 (3): H365-372.